Skip to content
ChickenStockChickenStock
ResearchCRSP
Crispr Therapeutics logo

Crispr Therapeutics (CRSP) stock

NASDAQ

$42.24-0.89%(-0.38)

As of the Nov 13, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-8.98x

Net loss — not comparable

P/B

2.49x

P/S

163.88x

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 1,200.0% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 2, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

17 SEC filings
  • Kulkarni SamarthChief Executive Officer · Oct 19, 2026Open-market sale47,837 shares · $2.4M
    Avg. price $49.78311,899 shares held after
  • Kulkarni SamarthChief Executive Officer · Oct 16, 2026Option exercise100,000 shares
    359,736 shares held after
  • George SimeonDirector · Oct 14, 2026Open-market sale14,514 shares · $720K
    Avg. price $49.63315,486 shares held after
  • Kulkarni SamarthChief Executive Officer · Oct 14, 2026Open-market sale4,098 shares · $202K
    Avg. price $49.26259,736 shares held after
  • KASINGER JAMES R.General Counsel and Secretary · Oct 14, 2026Open-market sale1,040 shares · $51K
    Avg. price $49.2695,857 shares held after
  • George SimeonDirector · Oct 14, 2026Option exercise30,000 shares · $420K
    Avg. price $1430,000 shares held after
  • Kulkarni SamarthChief Executive Officer · Oct 13, 2026Option exercise8,333 shares
    263,834 shares held after
  • KASINGER JAMES R.General Counsel and Secretary · Oct 13, 2026Option exercise2,113 shares
    96,897 shares held after
  • KASINGER JAMES R.General Counsel and Secretary · Oct 6, 2026Open-market sale1,990 shares · $119K
    Avg. price $60.040894,784 shares held after
  • KASINGER JAMES R.General Counsel and Secretary · Oct 6, 2026Option exercise1,990 shares · $27K
    Avg. price $13.6296,774 shares held after
  • KASINGER JAMES R.General Counsel and Secretary · Sep 22, 2026Open-market sale10,400 shares · $626K
    Avg. price $60.236594,784 shares held after
  • KASINGER JAMES R.General Counsel and Secretary · Sep 22, 2026Option exercise10,400 shares · $142K
    Avg. price $13.62105,184 shares held after
  • Behbahani AliDirector · Sep 17, 2026Open-market sale13,679 shares · $781K
    Avg. price $57.090116,637 shares held after
  • Behbahani AliDirector · Sep 17, 2026Option exercise30,000 shares · $420K
    Avg. price $1430,316 shares held after
  • Prasad RajuChief Financial Officer · Aug 7, 2026Gift750 shares · $0
    Avg. price $014,815 shares held after
  • Behbahani AliDirector · Aug 6, 2025Other75 shares · $0
    Avg. price $0
    Show 2 price lots
    • 60 shares × $0$0
    • 15 shares × $0$0

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Crispr Therapeutics (CRSP) stock information

NASDAQ

Crispr Therapeutics (CRSP) is listed on NASDAQ. Its market capitalization is about $4.1B. On trailing-twelve-month earnings the P/E ratio is -8.98, and the P/B ratio is 2.49. Return on equity is -27.7%. These figures are computed in-house from official filings and are reference information only.

Crispr Therapeutics — frequently asked questions

What is the P/E ratio of Crispr Therapeutics (CRSP)?
On a trailing-twelve-month basis, CRSP trades at a P/E ratio of -8.98. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Crispr Therapeutics?
CRSP has a market capitalization of about $4.1B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.